{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:38:36Z","timestamp":1791923916481,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41440-026-02561-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:24:45Z","timestamp":1770089085000},"page":"1336-1342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aldosterone\u2013mineralocorticoid receptor interactions: new insights and therapeutic perspectives in primary aldosteronism"],"prefix":"10.1038","volume":"49","author":[{"given":"Yuichi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2561_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"2561_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1097\/01.ASN.0000061777.67332.77","volume":"14","author":"OG Muller","year":"2003","unstructured":"Muller OG, Parnova RG, Centeno G, Rossier BC, Firsov D, Horisberger JD. Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na+ and K+. J Am Soc Nephrol. 2003;14:1107\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"2561_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1161\/HYPERTENSIONAHA.111.190512","volume":"59","author":"F Azibani","year":"2012","unstructured":"Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension. 2012;59:1179\u201387.","journal-title":"Hypertension"},{"key":"2561_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/ATVBAHA.113.302854","volume":"34","author":"D Pruthi","year":"2014","unstructured":"Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol. 2014;34:355\u201364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2561_CR5","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1172\/JCI43124","volume":"121","author":"S Shibata","year":"2011","unstructured":"Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Investig. 2011;121:3233\u201343.","journal-title":"J Clin Investig"},{"key":"2561_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41440-022-01036-6","volume":"46","author":"R Jo","year":"2023","unstructured":"Jo R, Shibata H, Kurihara I, Yokota K, Kobayashi S, Murai-Takeda A, et al. Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification. Hypertens Res. 2023;46:19\u201331.","journal-title":"Hypertens Res"},{"key":"2561_CR7","first-page":"2203","volume":"80","author":"Z Krozowski","year":"1995","unstructured":"Krozowski Z, MaGuire JA, Stein-Oakley AN, Dowling J, Smith RE, Andrews RK. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab. 1995;80:2203\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2561_CR8","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1210\/endo.137.12.8940344","volume":"137","author":"J Funder","year":"1996","unstructured":"Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 1996;137:5264\u20138.","journal-title":"Endocrinology"},{"key":"2561_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/HYPERTENSIONAHA.115.06977","volume":"67","author":"JR Ivy","year":"2016","unstructured":"Ivy JR, Oosthuyzen W, Peltz TS, Howarth AR, Hunter RW, Dhaun N, et al. Glucocorticoids induce nondipping blood pressure by activating the thiazide-sensitive cotransporter. Hypertension. 2016;67:1029\u201337.","journal-title":"Hypertension"},{"key":"2561_CR10","doi-asserted-by":"publisher","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","volume":"280","author":"N Farman","year":"2001","unstructured":"Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Ren Physiol. 2001;280:F181\u201392.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2561_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","volume":"10","author":"JW Funder","year":"2005","unstructured":"Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15\u201322.","journal-title":"Heart Fail Rev"},{"key":"2561_CR12","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2561_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2561_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2561_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu J, Zhou Q, Sun Y, Feng Z, Yang J, He W, et al. Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial. Circulation. 2025;151:196\u20138.","journal-title":"Circulation"},{"key":"2561_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"2561_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41440-021-00756-5","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes. Hypertens Res. 2022;45:97\u2013105.","journal-title":"Hypertens Res"},{"key":"2561_CR18","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2561_CR19","first-page":"5158","volume":"39","author":"HA Uchida","year":"2022","unstructured":"Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, et al. Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label, prospective study. Adv Ther. 2022;39:5158\u201375.","journal-title":"Adv Ther"},{"key":"2561_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Iijima S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens Res. 2021;44:489\u201397.","journal-title":"Hypertens Res"},{"key":"2561_CR21","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s12325-024-02780-6","volume":"41","author":"E Yamamoto","year":"2024","unstructured":"Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K, et al. Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study: a multicenter, open-label, prospective, interventional study. Adv Ther. 2024;41:1284\u2013303.","journal-title":"Adv Ther"},{"key":"2561_CR22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41440-023-01292-0","volume":"46","author":"K Kario","year":"2023","unstructured":"Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, et al. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study. Hypertens Res. 2023;46:1782\u201394.","journal-title":"Hypertens Res"},{"key":"2561_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41440-023-01412-w","volume":"47","author":"Y Yoshida","year":"2024","unstructured":"Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism. Hypertens Res. 2024;47:157\u201367.","journal-title":"Hypertens Res"},{"key":"2561_CR24","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u201346.","journal-title":"Hypertens Res"},{"key":"2561_CR25","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1038\/s41440-024-01818-0","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Katsuya T, Wada J, Motoki H, Kuwahara K, Tsujita K, et al. Factors influencing the efficacy and safety of esaxerenone in hypertensive patients: a pooled analysis of five clinical studies on different comorbidities. Hypertens Res. 2024;47:2826\u201339.","journal-title":"Hypertens Res"},{"key":"2561_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pr Nephrol. 2007;3:486\u201392.","journal-title":"Nat Clin Pr Nephrol"},{"key":"2561_CR27","doi-asserted-by":"publisher","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg K, Johansson U, Edman K, William-Olsson L, Myhre S, Gunnarsson A, et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE. 2018;13:e0193380.","journal-title":"PLoS ONE"},{"key":"2561_CR28","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/ejhf.3294","volume":"26","author":"CSP Lam","year":"2024","unstructured":"Lam CSP, Kober L, Kuwahara K, Lund LH, Mark PB, Mellbin LG, et al. Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial. Eur J Heart Fail. 2024;26:1727\u201335.","journal-title":"Eur J Heart Fail"},{"key":"2561_CR29","doi-asserted-by":"crossref","unstructured":"Mark PB, De Sousa-Amorim E, Eriksson AL, Zachrisson ML, Guzman NJ, Miller MT, et al. Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial. Nephrol Dial Transplant. 2025;40:2280-8.","DOI":"10.1093\/ndt\/gfaf119"},{"key":"2561_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","volume":"57","author":"R Gros","year":"2011","unstructured":"Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442\u201351.","journal-title":"Hypertension"},{"key":"2561_CR31","doi-asserted-by":"publisher","first-page":"C532","DOI":"10.1152\/ajpcell.00203.2012","volume":"304","author":"R Gros","year":"2013","unstructured":"Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD. Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol. 2013;304:C532\u201340.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2561_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5575927","volume":"2021","author":"Z Tang","year":"2021","unstructured":"Tang Z, Li Q, Cheng Q, Mei M, Song Y, Du Z, et al. G protein-coupled estrogen receptor 1 (GPER1) mediates aldosterone-induced endothelial inflammation in a mineralocorticoid receptor-independent manner. Int J Endocrinol. 2021;2021:5575927.","journal-title":"Int J Endocrinol"},{"key":"2561_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1226458","volume":"14","author":"X Li","year":"2023","unstructured":"Li X, Kuang W, Qiu Z, Zhou Z. G protein-coupled estrogen receptor: a promising therapeutic target for aldosterone-induced hypertension. Front Endocrinol (Lausanne). 2023;14:1226458.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2561_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41440-024-01970-7","volume":"48","author":"Y Yoshida","year":"2025","unstructured":"Yoshida Y, Shibata H. Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism. Hypertens Res. 2025;48:854\u201361.","journal-title":"Hypertens Res"},{"key":"2561_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388:395\u2013405.","journal-title":"N Engl J Med"},{"key":"2561_CR36","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. Aldosterone Synthase Inhibition With Lorundrostat For Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023;330:1140\u201350.","journal-title":"JAMA"},{"key":"2561_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102576","volume":"71","author":"P Mulatero","year":"2024","unstructured":"Mulatero P, Wuerzner G, Groessl M, Sconfienza E, Damianaki A, Forestiero V, et al. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial. EClinicalMedicine. 2024;71:102576.","journal-title":"EClinicalMedicine"},{"key":"2561_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403:379\u201390.","journal-title":"Lancet"},{"key":"2561_CR39","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393:1363\u201374.","journal-title":"N Engl J Med"},{"key":"2561_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu AF, Freeman MW, Bancos I, Ben-Shlomo A, Hamidi O, Hamrahian AH, et al. Phase 2a study of baxdrostat in primary aldosteronism. N Engl J Med. 2025;393:515\u20138.","journal-title":"N Engl J Med"},{"key":"2561_CR41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392:1813\u201323.","journal-title":"N Engl J Med"},{"key":"2561_CR42","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2008-2116","volume":"94","author":"E Born-Frontsberg","year":"2009","unstructured":"Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u2019s Registry. J Clin Endocrinol Metab. 2009;94:1125\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"2561_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diab Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diab Endocrinol"},{"key":"2561_CR44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Y Ohno","year":"2018","unstructured":"Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, et al. Prevalence of Cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530\u20137.","journal-title":"Hypertension"},{"key":"2561_CR45","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1161\/HYPERTENSIONAHA.123.21895","volume":"80","author":"E Gkaniatsa","year":"2023","unstructured":"Gkaniatsa E, Zverkova Sandstr\u00f6m T, Rosengren A, Trimpou P, Olsson DS, Lind M, et al. Mortality in patients with primary aldosteronism: a Swedish nationwide study. Hypertension. 2023;80:2601\u201310.","journal-title":"Hypertension"},{"key":"2561_CR46","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41440-023-01458-w","volume":"47","author":"BC Lee","year":"2024","unstructured":"Lee BC, Tsai HH, Chen ZW, Chang CC, Huang JZ, Chang YY, et al. Aldosteronism is associated with more severe cerebral small vessel disease in hypertensive intracerebral hemorrhage. Hypertens Res. 2024;47:608\u201317.","journal-title":"Hypertens Res"},{"key":"2561_CR47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society Of Hypertension Guidelines For The Management Of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2561_CR48","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European Society of Hypertension. J Hypertens. 2020;38:1919\u201328.","journal-title":"J Hypertens"},{"key":"2561_CR49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327\u201359.","journal-title":"Endocr J"},{"key":"2561_CR50","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2025;110:2453\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"2561_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diab Endocrinol. 2018;6:51\u20139.","journal-title":"Lancet Diab Endocrinol"},{"key":"2561_CR52","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","volume":"80","author":"S Katsuragawa","year":"2023","unstructured":"Katsuragawa S, Goto A, Shinoda S, Inoue K, Nakai K, Saito J, et al. Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism. Hypertension. 2023;80:1909\u201320.","journal-title":"Hypertension"},{"key":"2561_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","volume":"13","author":"J Yang","year":"2025","unstructured":"Yang J, Burrello J, Goi J, Reincke M, Adolf C, Asbach E, et al. Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diab Endocrinol. 2025;13:119\u201333.","journal-title":"Lancet Diab Endocrinol"},{"key":"2561_CR54","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/HJH.0000000000002922","volume":"39","author":"G Parati","year":"2021","unstructured":"Parati G, Stergiou GS, Bilo G, Kollias A, Pengo M, Ochoa JE, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the working group on blood pressure monitoring and cardiovascular variability of the European Society of Hypertension. J Hypertens. 2021;39:1742\u201367.","journal-title":"J Hypertens"},{"key":"2561_CR55","doi-asserted-by":"crossref","unstructured":"Chu WK, Lai CF, Chiang S, Lin YH, Chen YL, Wu VC. Primary aldosteronism and long-term outcomes using the PAMO definition. Hypertens Res. 2025;49:457\u201368.","DOI":"10.1038\/s41440-025-02324-7"},{"key":"2561_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41440-022-01045-5","volume":"46","author":"Y Yoshida","year":"2023","unstructured":"Yoshida Y, Fujiki R, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: the potential importance of post-treatment plasma renin levels. Hypertens Res. 2023;46:100\u20137.","journal-title":"Hypertens Res"},{"key":"2561_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41440-024-01997-w","volume":"48","author":"N Matsuda","year":"2025","unstructured":"Matsuda N, Yoshida Y, Inobe N, Yoshimura M, Iwamoto M, Nagai S, et al. Antihypertensive effects and changes in extracellular water content by mineralocorticoid receptor antagonists in patients with primary aldosteronism. Hypertens Res. 2025;48:553\u201362.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02561-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02561-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T22:02:17Z","timestamp":1775426537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02561-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2561"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02561-4","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HS has received honoraria for lectures from Bayer, Daiichi Sankyo, and AstraZeneca. HS is a member of the Executive Committee for baxdrostat (AstraZeneca).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}